Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA INQUIRY ALERT: A Securities Fraud Investigation has been Initiated against ADMA Biologics into the Auditor Resignation; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent outside auditor, CohnReznick LLP. This development has led to a dramatic decline in ADMA's stock price, which fell by more than 20% during trading shortly after the announcement on October 9, 2024. Investors who have suffered losses are being encouraged to seek legal guidance from securities law firm Bleichmar Fonti & Auld LLP, which is pursuing a class action lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics faces a securities fraud investigation following the resignation of its independent auditor.
  • The stock price dropped over 20% immediately after the auditor's resignation announcement.
  • Investors have incurred significant losses due to the stock decline.

Full Press Release Details

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What caused the drop in ADMA Biologics's stock?

The stock fell due to the unexpected resignation of its independent auditor.

What is Bleichmar Fonti & Auld LLP investigating?

They are investigating ADMA Biologics for potential federal securities law violations.

What should ADMA Biologics investors do?

Investors are encouraged to seek more information and consider legal options.

Are there costs for ADMA Biologics shareholders seeking help?

No, shareholders won't pay litigation costs; representation is on a contingency basis.

What distinguishes Bleichmar Fonti & Auld LLP?

It is recognized for its success in securities class actions and shareholder litigation.

Last updated: Nov 4, 2024